This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Cramer's 'Mad Money' Recap: Bright Spots

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- With the markets geared for disappointment, most investors are expecting the worst, Jim Cramer told "Mad Money" viewers Wednesday.

But that doesn't mean that there aren't bright spots in the market, he continued, stocks like Stryker (SYK), Seagate (STX) and even Alcoa (AA), all of which were all able to surprise Wall Street to the upside.

That's why Cramer continued his week-long series of macro themes that will trump no matter what negativity 2013 may throw at us. Tonight's themes included aerospace and China.

Despite a string of problems with Boeing's (BA) 787 Dreamliner this week, Cramer said the need for new planes is still in full effect. Alcoa mentioned during its conference call that there are still some 8,900 planes on order because for the first time in many years airlines have the financing available to buy them.

That's why Cramer said he's buying more United Technologies (UTX), a stock he owns for his charitable trust, Action Alerts PLUS, but he also likes Honeywell (HON).

Then there's China, a country that's accelerating its expansion after a year of focusing on the wrong metric of interest rates. Cramer said that Joy Global (JOY) remains a popular China play, but he's still a fan of the iShares FTSE China 25 (FXI) ETF as it offers a basket of Chinese stocks, making it easier to invest.

Cramer said either of these two themes would make excellent investments on the next big down day for the markets.

Executive Decision

In the "Executive Decision" segment, Cramer spoke with Dr. Ron Cohen, president and CEO of Acorda Therapeutics (ACOR), a biotech firm whose drug Ampyra is helping those with muscular sclerosis regain their mobility. Shares of Acorda are up 15% since Cramer last spoke with Cohen in July.

Cohen said that so far about 70,000 patients with MS have tried Ampyra and are having great success, but there are still an estimated 130,000 more who have walking disabilities that can benefit from the drug. Acorda is also in clinical trials testing Ampyra for other indications including cerebral palsy and chronic stroke.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs